ArticleAdvances in therapy2025

Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).

Eric Simpson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.